Market Closed -
Nasdaq
01:30:01 03/05/2024 am IST
|
5-day change
|
1st Jan Change
|
9.51
USD
|
+0.85%
|
|
+12.41%
|
+159.84%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,449
|
590.2
|
82.66
|
146.7
|
677.8
|
-
|
-
|
Enterprise Value (EV)
1 |
3,368
|
456.6
|
-59.49
|
61.17
|
493.5
|
578.3
|
470.7
|
P/E ratio
|
-30.5
x
|
-6
x
|
-1.2
x
|
-1.5
x
|
-5.94
x
|
-6.43
x
|
-6.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
201
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
140
x
|
EV / EBITDA
|
-106
x
|
-5
x
|
0.94
x
|
-0.67
x
|
-5.63
x
|
-5.88
x
|
-4.28
x
|
EV / FCF
|
-139
x
|
-9.97
x
|
1.19
x
|
-0.95
x
|
-7.05
x
|
-6.83
x
|
-3.95
x
|
FCF Yield
|
-0.72%
|
-10%
|
84.3%
|
-105%
|
-14.2%
|
-14.6%
|
-25.3%
|
Price to Book
|
-
|
-
|
-
|
1.83
x
|
3.59
x
|
6.41
x
|
3.67
x
|
Nbr of stocks (in thousands)
|
75,377
|
28,511
|
37,571
|
40,095
|
71,872
|
-
|
-
|
Reference price
2 |
45.75
|
20.70
|
2.200
|
3.660
|
9.430
|
9.430
|
9.430
|
Announcement Date
|
30/03/21
|
28/03/22
|
09/03/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.367
|
EBITDA
1 |
-
|
-31.89
|
-91.24
|
-63.15
|
-90.7
|
-87.65
|
-98.3
|
-110
|
EBIT
1 |
-
|
-
|
-93.85
|
-66.33
|
-93.87
|
-95.07
|
-110.6
|
-131.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,913.24%
|
Earnings before Tax (EBT)
1 |
-
|
-35.34
|
-94.19
|
-56.8
|
-95.73
|
-91.58
|
-104
|
-117.8
|
Net income
1 |
-5.474
|
-35.34
|
-93.04
|
-56.8
|
-95.73
|
-94.54
|
-106
|
-120.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,592.52%
|
EPS
2 |
-0.7500
|
-1.500
|
-3.450
|
-1.840
|
-2.440
|
-1.587
|
-1.467
|
-1.428
|
Free Cash Flow
1 |
-
|
-24.18
|
-45.82
|
-50.14
|
-64.36
|
-69.95
|
-84.7
|
-119.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,539.11%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
30/03/21
|
28/03/22
|
09/03/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-20.01
|
-24.29
|
-17.72
|
-16.12
|
-16.19
|
-13.11
|
-20.07
|
-28.39
|
-20.82
|
-21.42
|
-20.05
|
-21.05
|
-22.65
|
-23.9
|
-
|
EBIT
1 |
-23.28
|
-19.2
|
-18.5
|
-16.94
|
-16.98
|
-13.9
|
-20.86
|
-29.18
|
-21.62
|
-22.2
|
-22.09
|
-23.13
|
-24.33
|
-26.22
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-23.14
|
-19.9
|
-18.45
|
-16.96
|
-16.48
|
-4.903
|
-24.82
|
-29.13
|
-17.92
|
-23.86
|
-21.41
|
-22.26
|
-23.28
|
-24.78
|
-
|
Net income
1 |
-23.14
|
-18.75
|
-18.45
|
-16.96
|
-16.48
|
-4.903
|
-24.82
|
-29.13
|
-17.92
|
-23.86
|
-25.76
|
-21.48
|
-22.65
|
-25.25
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9000
|
-0.7500
|
-0.6000
|
-0.6000
|
-0.5600
|
-0.0200
|
-0.6500
|
-0.7600
|
-0.4500
|
-0.5900
|
-0.5433
|
-0.3600
|
-0.3767
|
-0.4133
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
28/03/22
|
16/05/22
|
11/08/22
|
10/11/22
|
09/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
80.1
|
134
|
142
|
85.6
|
184
|
99.5
|
207
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-24.2
|
-45.8
|
-50.1
|
-64.4
|
-70
|
-84.7
|
-119
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-83.6%
|
-65%
|
-70.1%
|
-70.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
2.000
|
2.630
|
1.470
|
2.570
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-1.640
|
-0.8700
|
-1.080
|
-1.000
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
4
|
10
|
12.5
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
371.29%
|
Announcement Date
|
30/03/20
|
30/03/21
|
28/03/22
|
09/03/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
9.51
USD Average target price
30.86
USD Spread / Average Target +224.47% Consensus |
1st Jan change
|
Capi.
|
---|
| +159.84% | 678M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|